Life, as they say, is full of surprises. But how many of them are genuine? Every now and then something pops up that'll genuinely catch you off guard. That's the case with my recent drive on the Akagi ...
A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory ...
LONDON and GAITHERSBURG, Md., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering ...
Further Validates NeuroOne's Patented Platform Technology for Both Brain Ablation and Pain Management Procedures EDEN PRAIRIE, MINN. - December 9, 2025 (NEWMEDIAWIRE) - NeuroOne Medical Technologies ...
Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish the maximum tolerated dose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback